Immutep

Immutep is a multinational biotechnology business that is a pioneer in the development of LAG-3-related immunotherapeutic medicines for cancer and autoimmune disease therapy. Immutep is committed to maximizing shareholder value by utilizing its technology and experience to bring breakthrough therapeutic solutions to the market for patients.

Immutep has been a pioneer in developing treatments to either activate or inhibit the immune system in order to fight cancer or get rid of autoimmune diseases. It now has a diverse portfolio of cutting-edge immuno-oncology and targeted LAG-3 immunotherapy prospects, comprising three clinical-stage candidates, one pre-clinical candidate, and one early-stage candidate.

Immutep's current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 fusion protein (LAG-3Ig) that is being studied in cancer and infectious diseases. Immutep is also working on a LAG-3 agonist (IMP761) for autoimmune disease. Immutep's significant pharmaceutical partners are developing other LAG-3 medicines, including antibodies for immune response modulation.

Founded: 2001

Headquarters: Sydney, NSW, Australia

Website: https://www.immutep.com/